TCB Self-Monitoring in Healthy Term and Near-Term Neonates

Launched by NEONATAL-INFANT BRAIN AND BEHAVIOR DEVELOPMENT NETWORK · Oct 15, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the levels of bilirubin in healthy newborns, specifically looking at how these levels change over the first month of life. Bilirubin is a substance in the blood that can cause a condition called hyperbilirubinemia, which is when there is too much bilirubin, often leading to jaundice (yellowing of the skin and eyes). The researchers aim to create a guide (called a nomogram) to help identify which babies might be at risk for this condition. They will also compare bilirubin levels across different regions and types of newborns in China.

To participate in this study, babies must be born at or after 35 weeks of pregnancy and be less than 30 days old. However, babies who have received treatment with phototherapy (a light treatment for jaundice) within the first 60 hours after birth will not be included in the study. Families can expect to have their baby's bilirubin levels monitored regularly, which is a simple and non-invasive process. This study is important as it may help improve how doctors assess and manage bilirubin levels in newborns, ensuring healthier outcomes for infants.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Gestational age \>=35wk; did not admitted to hospital for any reason Less than 30 days of age
• Exclusion Criteria:
• • Accept phototherapy within 60h of age